ON203

In vivo, ON203 mAb demonstrated superior efficacy over imalumab in both prophylactic and established prostate cancer (PC3) mouse xenograft models. In summary, our data highlight the potential of the second-generation anti-oxMIF mAb ON203 as a promising immunotherapy for patients with solid tumors, warranting clinical evaluation.

Taken together, the anti-oxMIF antibody ON203 demonstrated antitumorigenic effects by reducing tumor cell proliferation and by modulating the TME towards immunosupportive functions. In the upcoming clinical Phase 1 trial ON203’s safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with solid tumors will be analyzed to evaluate its potential as a standalone or combinatorial therapy with immune checkpoint inhibitors.

Conclusions The anti-oxMIF antibody ON203 demonstrated antitumorigenic effects by (i) reducing tumor cell proliferation, (ii) reducing angiogenesis and intravasation and (iii) by modulating the TME towards immunosupportive functions. In the upcoming clinical Phase 1 trial ON203’s safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with solid tumors will be analyzed to evaluate its potential as a standalone or combinatorial therapy with immune checkpoint inhibitors, kinase inhibitors or antiangiogenic agents.

Our results substantiate a Ph 1 trial evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with solid tumors. Conclusion ON203 has a high potential to become a new treatment option for patients with solid tumors as a standalone therapy or in combination with checkpoint inhibitors, chemotherapeutics, anti-angiogenic drugs, or kinase inhibitors.

ON203 has a high potential to significantly improve efficacy compared to the 1st generation anti-oxMIF mAb, with Zr89-ON102 as companion diagnostic for patient stratification. We aim to develop these anti-oxMIF mAbs together for clinical use to create new treatment options for patients with solid tumors, with a clear rationale to combine ON203 with other immunotherapies or checkpoint inhibitors (Noe and Mitchell, 2020).